Consensus revenue for the second quarter is estimated at $0.0 million as Shuttle Pharmaceuticals remains a pre-revenue entity, while formal analyst EPS expectations are currently unavailable following the company's radical pivot into digital asset mining. Investors are primarily focused on the company's status regarding a Nasdaq non-compliance notice received on August 28, 2026, due to the delayed filing of this Q2 10-Q report.
Since its transformative merger with United Dogecoin Inc. in May 2026, the company has pivoted toward Dogecoin mining infrastructure, leading to a 95% year-over-year reduction in pharmaceutical research and development spending. Markets are closely monitoring whether the newly rebranded "United Compute" can successfully deploy its initial 500-rig mining fleet while maintaining its legacy oncology pipeline.